The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon.

Abstract

OBJECTIVES The aim of the study was to assess the angiographic and clinical benefits of the calcium T-channel blocker, mibefradil, in the coronary slow flow phenomenon (CSFP). BACKGROUND The CSFP is characterized by delayed vessel opacification on angiography (Thrombolysis In Myocardial Infarction [TIMI]-2 flow) in the absence of obstructive epicardial… (More)

Topics

3 Figures and Tables